Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibodies and small molecule therapeutics - MediaPharma

Drug Profile

Research programme: monoclonal antibodies and small molecule therapeutics - MediaPharma

Alternative Names: mab EV20; MP BF 001; MP-1959 (SP-2); MP-3546; MP-AA-1; MP-E-8-3/1959; MP-E-8.3; MP-EV-20; MP-EV20-DC54; MP-EV20-RT; MP-HE-001A; MP-HE-001B; MP-HE-001C; MP-PN-1; MP-PN-2; MP-RM-1 (ErbB-3 antibody)

Latest Information Update: 28 Oct 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediaPharma
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
  • Mechanism of Action Carrier protein inhibitors; CD248 antigen inhibitors; Epidermal growth factor receptor modulators; ERBB-3 receptor antagonists; Hypoxia inducible factor 1 inhibitors; Hypoxia-inducible factor 1 alpha inhibitors; Receptor protein-tyrosine kinase modulators; Transcriptional elongation factor inhibitors; Transcriptional elongation factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Diabetic foot ulcer; Pancreatic cancer; Phaeochromocytoma; Renal cell carcinoma; Stroke; Von Hippel-Lindau disease

Most Recent Events

  • 28 Oct 2020 No recent reports of development identified for preclinical development in Pancreatic-cancer in Italy
  • 28 Oct 2020 No recent reports of development identified for preclinical development in Phaeochromocytoma in Italy
  • 28 Oct 2020 No recent reports of development identified for preclinical development in Renal-cell-carcinoma in Italy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top